Bristol Myers Reaches $239 Million Settlement Over Psoriasis, MS Drugs
Insurance Journal - Nov 07, 2025
Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now known as Zeposia. A preliminary settlement of the 7-1/2-year-old class action was …...
Recommended Articles
Posted: Apr 16, 2026
The medical officer for the Texas summer camp where 27 girls were killed in a flood last year testif...
Posted: Apr 16, 2026
Utah-based insurance broker Trucordia reports it has acquired the Paradiso Financial and Insurance S...
Posted: Apr 16, 2026
Inszone Insurance Services announced the acquisition of Insurance Resources Group, Inc. Located in O...